Comparative Studies on the Human Serum Albumin Binding of the Investigational EGFR Inhibitor KP2187, Its Hypoxia-Activated Cobalt Complex, and a Series of Clinically Approved Inhibitors †
Acknowledgments
References
- Karnthaler-Benbakka, C.; Groza, D.; Kryeziu, K.; Pichler, V.; Roller, A.; Berger, W.; Heffeter, P.; Kowol, C.R. Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation. Angew. Chem. Int. Ed. 2014, 53, 12930–12935. [Google Scholar] [CrossRef] [PubMed]
- Dömötör, O.; Pelivan, K.; Borics, A.; Keppler, B.K.; Kowol, C.R.; Enyedy, É.A. Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187. J. Pharm. Biomed. Anal. 2018, 154, 321–331. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Enyedy, E.A.; Dömötör, O.; Borics, A.; Keppler, B.K.; Kowol, C.R. Comparative Studies on the Human Serum Albumin Binding of the Investigational EGFR Inhibitor KP2187, Its Hypoxia-Activated Cobalt Complex, and a Series of Clinically Approved Inhibitors. Proceedings 2019, 22, 27. https://doi.org/10.3390/proceedings2019022027
Enyedy EA, Dömötör O, Borics A, Keppler BK, Kowol CR. Comparative Studies on the Human Serum Albumin Binding of the Investigational EGFR Inhibitor KP2187, Its Hypoxia-Activated Cobalt Complex, and a Series of Clinically Approved Inhibitors. Proceedings. 2019; 22(1):27. https://doi.org/10.3390/proceedings2019022027
Chicago/Turabian StyleEnyedy, Eva Anna, Orsolya Dömötör, Attila Borics, Bernhard K. Keppler, and Christian R. Kowol. 2019. "Comparative Studies on the Human Serum Albumin Binding of the Investigational EGFR Inhibitor KP2187, Its Hypoxia-Activated Cobalt Complex, and a Series of Clinically Approved Inhibitors" Proceedings 22, no. 1: 27. https://doi.org/10.3390/proceedings2019022027
APA StyleEnyedy, E. A., Dömötör, O., Borics, A., Keppler, B. K., & Kowol, C. R. (2019). Comparative Studies on the Human Serum Albumin Binding of the Investigational EGFR Inhibitor KP2187, Its Hypoxia-Activated Cobalt Complex, and a Series of Clinically Approved Inhibitors. Proceedings, 22(1), 27. https://doi.org/10.3390/proceedings2019022027